{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:29:54Z","timestamp":1789532994944,"version":"build-2803163510"},"reference-count":33,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Disease relapse is recognized as a risk in immune-mediated thrombotic thrombocytopenic purpura (iTTP) after treatment of the acute presenting episode. Identification of patients at risk of relapse and its patterns are yet to be clearly established. We reviewed patients with iTTP having had &amp;gt;3 years of follow-up over 10 years in the United Kingdom to identify patient characteristics for relapse, assess relapse rates and patterns, and response to anti-CD20 therapy in those with a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) relapses (ADAMTS13 activity of &amp;lt;20% without thrombocytopenia). We identified 443 patients demonstrating relapse rates of 40% at 5-year follow-up. At 10-year follow-up, no difference in relapse was observed irrespective of whether rituximab was used at acute presentation (P\u00a0= .39). Black Caribbean ethnicity increased the risk of disease relapse in the British population. There was a distinct population of patients (6%) that relapsed early with subsequent frequent relapses occurring on average within 2 years (average time to relapse in subgroup, 1.7 years). Overall, nearly 60% of relapses described were ADAMTS13 relapses, with subsequent treatment reducing the risk of progression to clinical relapses. We demonstrate that iTTP diagnosed in the latter part of the study period had lower rates of clinical relapses (22.6% vs 11.1%, P\u00a0= .0004) with the advent of regular monitoring and preemptive rituximab. In ADAMTS13 relapses, 96% responded to anti-CD20 therapy, achieving ADAMTS13 activity of &amp;gt;20%. Anti-CD20 therapy was demonstrated to be an effective long-term treatment regardless of relapse pattern and there was no loss of this treatment response after subsequent treatment episodes.<\/jats:p>","DOI":"10.1182\/blood.2022017023","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T22:27:16Z","timestamp":1667428036000},"page":"285-294","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1001-0486","authenticated-orcid":false,"given":"Andrew J.","family":"Doyle","sequence":"first","affiliation":[{"name":"1University College London Hospitals NHS Foundation Trust, London, United Kingdom"},{"name":"2Guy\u2019s and St Thomas\u2019s NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0665-4625","authenticated-orcid":false,"given":"Matthew J.","family":"Stubbs","sequence":"additional","affiliation":[{"name":"1University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Dutt","sequence":"additional","affiliation":[{"name":"3Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8790-7112","authenticated-orcid":false,"given":"Will","family":"Lester","sequence":"additional","affiliation":[{"name":"4University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Thomas","sequence":"additional","affiliation":[{"name":"5Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6921-9287","authenticated-orcid":false,"given":"Joost","family":"van Veen","sequence":"additional","affiliation":[{"name":"6Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5703-512X","authenticated-orcid":false,"given":"Joannes","family":"Hermans","sequence":"additional","affiliation":[{"name":"7Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Cranfield","sequence":"additional","affiliation":[{"name":"8Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0627-4358","authenticated-orcid":false,"given":"Quentin A.","family":"Hill","sequence":"additional","affiliation":[{"name":"9Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Clark","sequence":"additional","affiliation":[{"name":"10University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-9706","authenticated-orcid":false,"given":"Catherine","family":"Bagot","sequence":"additional","affiliation":[{"name":"11NHS Greater Glasgow and Clyde, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Austin","sequence":"additional","affiliation":[{"name":"2Guy\u2019s and St Thomas\u2019s NHS Foundation Trust, London, United Kingdom"},{"name":"12St George\u2019s University Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Paul","family":"Westwood","sequence":"additional","affiliation":[{"name":"1University College London Hospitals NHS Foundation Trust, London, United Kingdom"},{"name":"13Cardiometabolic Programme, National Institute for Health Research, University College London Hospitals\/University College London Biomedical Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Thomas","sequence":"additional","affiliation":[{"name":"1University College London Hospitals NHS Foundation Trust, London, United Kingdom"},{"name":"13Cardiometabolic Programme, National Institute for Health Research, University College London Hospitals\/University College London Biomedical Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Scully","sequence":"additional","affiliation":[{"name":"1University College London Hospitals NHS Foundation Trust, London, United Kingdom"},{"name":"13Cardiometabolic Programme, National Institute for Health Research, University College London Hospitals\/University College London Biomedical Research Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2023082419142874400_bib1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ebiom.2015.06.007","article-title":"Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"2","author":"Thomas","year":"2015","journal-title":"EBioMedicine"},{"issue":"7","key":"2023082419142874400_bib2","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A\u00a0phase 2 study of the safety and efficacy\u00a0of\u00a0rituximab with plasma exchange in acute\u00a0acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2023082419142874400_bib3","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2023082419142874400_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"issue":"20","key":"2023082419142874400_bib5","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2023082419142874400_bib6","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/bloodadvances.2019031039","article-title":"Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura","volume":"3","author":"Sun","year":"2019","journal-title":"Blood Adv"},{"key":"2023082419142874400_bib7","doi-asserted-by":"crossref","first-page":"1076029618825309","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb\u00a0Hemost"},{"issue":"8","key":"2023082419142874400_bib8","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2023082419142874400_bib9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s12185-020-02974-y","article-title":"Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan","volume":"112","author":"Kubo","year":"2020","journal-title":"Int J Hematol"},{"issue":"2","key":"2023082419142874400_bib10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2023082419142874400_bib11","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2023082419142874400_bib12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing\u00a0thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"2023082419142874400_bib13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"12","key":"2023082419142874400_bib14","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood.2022016640","article-title":"Race, rituximab, and relapse in TTP","volume":"140","author":"Chaturvedi","year":"2022","journal-title":"Blood"},{"key":"2023082419142874400_bib15","unstructured":"GOV.UK . Black Caribbean ethnic group: facts and figures. Updated 27 June 2019. Accessed 22 February 2022. https:\/\/www.ethnicity-facts-figures.service.gov.uk\/summaries\/black-caribbean-ethnic-group."},{"issue":"26","key":"2023082419142874400_bib16","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood.2020005395","article-title":"HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR","volume":"135","author":"Sakai","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2023082419142874400_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13052-019-0641-y","article-title":"Clinical features and prognosis of patients with thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a review of 25 cases","volume":"45","author":"Li","year":"2019","journal-title":"Ital J Pediatr"},{"issue":"9","key":"2023082419142874400_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-019-0271-1","article-title":"Is ethnicity linked to the severity of SLE manifestations?","volume":"15","author":"Kabani","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"suppl 1","key":"2023082419142874400_bib20","first-page":"i67","article-title":"The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus","volume":"56","author":"Lewis","year":"2017","journal-title":"Rheumatology"},{"issue":"3","key":"2023082419142874400_bib21","first-page":"353","article-title":"Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura","volume":"136","author":"Roose","year":"2020","journal-title":"Blood"},{"issue":"15","key":"2023082419142874400_bib22","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","article-title":"Characterization and treatment of congenital thrombotic thrombocytopenic purpura","volume":"133","author":"Alwan","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2023082419142874400_bib23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40271-019-00365-y","article-title":"Patient experience with congenital (hereditary) thrombotic thrombocytopenic purpura: a conceptual framework of symptoms and impacts","volume":"12","author":"Oladapo","year":"2019","journal-title":"Patient"},{"issue":"5","key":"2023082419142874400_bib24","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/bjh.15874","article-title":"Comparison of rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura","volume":"185","author":"Stubbs","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"2023082419142874400_bib25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bjh.18192","article-title":"The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura","volume":"198","author":"Doyle","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"2023082419142874400_bib26","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1002\/ajh.25002","article-title":"No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: the experience from the Ohio State University registry","volume":"93","author":"Masias","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"2023082419142874400_bib27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2141.2010.08385.x","article-title":"Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura [published correction appears in Br J Haematol. 2011;152(3):364]","volume":"151","author":"Lotta","year":"2010","journal-title":"Br J Haematol"},{"issue":"10","key":"2023082419142874400_bib28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00277-009-0707-9","article-title":"Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment","volume":"88","author":"Alvarez-Larr\u00e1n","year":"2009","journal-title":"Ann Hematol"},{"issue":"3","key":"2023082419142874400_bib29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/bloodadvances.2019000827","article-title":"Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura","volume":"4","author":"Goshua","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2023082419142874400_bib30","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood-2003-05-1616","article-title":"Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura","volume":"102","author":"Scheiflinger","year":"2003","journal-title":"Blood"},{"issue":"8","key":"2023082419142874400_bib31","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1182\/blood-2010-01-262709","article-title":"ADAMTS13 testing: why bother?","volume":"115","author":"Zheng","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2023082419142874400_bib32","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"2023082419142874400_bib33","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/cei.12472","article-title":"Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura","volume":"179","author":"Becerra","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"9767","key":"2023082419142874400_bib34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/3\/285\/2073535\/blood_bld-2022-017023-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/3\/285\/2073535\/blood_bld-2022-017023-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T03:54:43Z","timestamp":1728273283000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/3\/285\/486975\/Long-term-risk-of-relapse-in-immune-mediated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,1,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017023","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]}}}